Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals Inc (ELDN) is a clinical-stage biotechnology company pioneering targeted immunosuppressive therapies through its anti-CD40L antibody tegoprubart. This page serves as the definitive source for verified updates on the company's clinical developments, regulatory milestones, and research advancements.
Investors and medical professionals will find timely updates on kidney transplant trials, islet cell transplantation studies for diabetes, and xenotransplantation research. Our curated news collection includes FDA communications, partnership announcements, and peer-reviewed publication highlights related to ELDN's novel approach to immune-mediated conditions.
All content undergoes rigorous verification to ensure accuracy in reporting clinical trial phases, scientific collaborations, and therapeutic mechanism updates. The resource is particularly valuable for tracking progress in reducing transplant rejection risks and improving autoimmune disease management through CD40 pathway modulation.
Bookmark this page for structured access to ELDN's evolving clinical pipeline, including safety profile updates for tegoprubart and expansion into new therapeutic applications. Check regularly for objective reporting on this innovative approach to immune system regulation.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its Q4 and full year 2024 results, highlighting significant advances in organ transplantation. Their lead drug tegoprubart was successfully used in two landmark procedures: a genetically modified pig kidney transplant at Massachusetts General Hospital and islet transplants for type 1 diabetes patients at UChicago Medicine.
The company strengthened its financial position through an $85 million oversubscribed offering, extending their cash runway to end of 2026. As of December 31, 2024, cash and investments stood at $140.2 million.
For Q4 2024, R&D expenses were $17.9 million and G&A expenses were $6.8 million, with a net loss of $44.6 million ($0.64 per share). Full year 2024 resulted in a net loss of $36.2 million ($0.75 per share). The company expects topline results from their Phase 2 BESTOW trial in kidney transplantation by Q4 2025.
Eledon Pharmaceuticals (Nasdaq: ELDN) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. The company's Chief Scientific Officer and President, Steve Perrin, Ph.D., will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT).
Interested parties can register in advance for the webcast of the fireside chat. Following the live session, a replay will be made available on the Company's website under the Events section.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that its investigational anti-CD40L antibody, tegoprubart, was used in a successful xenotransplantation of a genetically modified pig kidney into a human at Massachusetts General Hospital (MGH) on January 25, 2025. The patient has been discharged and is now off dialysis for the first time in over two years.
This marks the second kidney xenotransplant at MGH using tegoprubart as a key component of the immunosuppression regimen. The FDA approved MGH to perform two additional xenotransplants this year. Tegoprubart was also used in the second-ever pig-to-human heart transplant at the University of Maryland Medical Center in September 2023.
The drug is currently being evaluated in three global clinical studies for organ rejection prevention in kidney transplants and in a separate trial for islet transplant rejection in type 1 diabetes patients. Eledon plans to report interim clinical trial results in summer 2025 and topline results from its Phase 2 BESTOW kidney transplant trial in Q4 2025.
Eledon Pharmaceuticals (Nasdaq: ELDN) has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's leadership, including CEO David-Alexandre C. Gros, M.D., and Chief Scientific Officer and President Steve Perrin, Ph.D., will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:00 p.m. ET (10:00 a.m. PT).
Interested parties can register in advance for the presentation webcast through a provided link. Following the live session, a replay of the webcast will be made available on the Company's website in the Events section.
Eledon Pharmaceuticals (Nasdaq: ELDN) announced significant milestones achieved in 2024 and provided their 2025 outlook.
Key 2024 highlights include:
- Completed enrollment in the Phase 2 BESTOW trial for tegoprubart in kidney transplantation four months early, with topline results expected in Q4 2025.
- Presented data from Phase 1b trial showing tegoprubart's safety and tolerability in preventing organ rejection in kidney transplants.
- Reported positive initial data from three type 1 diabetes patients treated with tegoprubart in an islet transplantation trial at UChicago Medicine.
- Utilized tegoprubart in the first-ever kidney xenotransplant from a genetically modified pig to a human.
- Completed two financings totaling $135 million, expected to fund operations through 2026.
For 2025, Eledon plans to:
- Report updated interim data from ongoing Phase 1b and long-term efficacy studies in summer 2025.
- Release topline results from the BESTOW trial in Q4 2025.
- Provide longer-term follow-up data from the islet transplantation trial at UChicago Medicine.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported Q3 2024 financial results and business updates. Key highlights include completed enrollment of Phase 2 BESTOW trial in kidney transplantation, positive initial data from type 1 diabetes islet transplantation trial, and an $85 million oversubscribed offering. The company reported Q3 net income of $77.0 million ($1.05 per share), primarily due to a non-cash gain of $96.4 million. R&D expenses increased to $16.5 million from $7.9 million year-over-year. Cash position stands at $78.2 million, with an additional $79.5 million from October offering, expected to fund operations through end of 2026.
Eledon Pharmaceuticals (Nasdaq: ELDN) has announced its participation in the Guggenheim Securities Inaugural Healthcare Innovation Conference. CEO David-Alexandre C. Gros, M.D., will engage in a fireside chat on Wednesday, November 13, 2024, at 1:30 p.m. ET (10:30 a.m. PT). The presentation will be available via webcast, with advance registration required. A replay of the session will be accessible on the company's investor relations website following the live event.
Eledon Pharmaceuticals announced the pricing of an $85 million underwritten offering, consisting of 18,356,173 shares of common stock at $3.65 per share and pre-funded warrants for 4,931,507 shares at $3.649 with a $0.001 exercise price. The offering, expected to close around October 30, 2024, includes participation from notable investors like BVF Partners LP, RA Capital Management, and others. The proceeds will be used to advance Eledon's pipeline and for working capital. Leerink Partners is acting as sole book-running manager, with Noble Capital Markets as financial advisor.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported positive initial data from a trial using tegoprubart for islet transplantation in Type 1 diabetes patients. Two out of three subjects achieved insulin independence and maintained normal glucose levels after treatment. The first two subjects showed three to five times higher islet engraftment compared to standard tacrolimus-based treatment. The first patient achieved insulin independence two weeks after a second transplant, while the second patient stopped insulin support four weeks post-transplant. The third subject reduced insulin use by over 60% three days after the procedure. The treatment was generally well tolerated with no unexpected adverse events.
Eledon Pharmaceuticals (NASDAQ: ELDN) has announced its participation in the upcoming Cantor Global Healthcare Conference. The company's CEO, David-Alexandre C. Gros, M.D., will engage in a fireside chat on Wednesday, September 18, 2024, at 8:35 a.m. ET.
Interested parties can register in advance for the webcast of the fireside chat. For those unable to attend live, a replay of the webcast will be made available on the company's website in the Events section following the session. This presentation at a major healthcare conference provides an opportunity for Eledon to showcase its developments and engage with industry professionals and investors.
FAQ
What is the current stock price of Eledon Pharmaceuticals (ELDN)?
What is the market cap of Eledon Pharmaceuticals (ELDN)?
